{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:07Z","timestamp":1792001467967,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012093","name":"Vall d'Hebron Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Open Respiratory Archives"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.opresp.2026.100578","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:23:03Z","timestamp":1768461783000},"page":"100578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitors and Interstitial Lung Disease: A Comprehensive Review of Pathogenesis, Diagnosis, and Management"],"prefix":"10.1016","volume":"8","author":[{"given":"Mar\u00eda Florencia","family":"Pilia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Espejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Andreu Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Clofent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Ojanguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.opresp.2026.100578_bib0245","first-page":"134","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","author":"Ghanbar","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.opresp.2026.100578_bib0250","first-page":"15","article-title":"Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.opresp.2026.100578_bib0255","first-page":"50","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2026.100578_bib0260","first-page":"22","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.opresp.2026.100578_bib0265","first-page":"15","article-title":"Incidences of pneumonitis associated with the combination of radiotherapy and immune checkpoint inhibitors in lung cancer: a systematic review and meta-analysis","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0270","first-page":"28","article-title":"Immune checkpoint inhibitor therapy-related pneumonitis: how, when and why to diagnose and manage (Review)","author":"Lavalle","year":"2024","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.opresp.2026.100578_bib0275","first-page":"17","article-title":"A systematic review of clinical practice guidelines for managing pulmonary toxicities caused by immune checkpoint inhibitors: quality of treatment recommendations and differences in management strategies between guidelines","author":"Donkor","year":"2023","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0280","first-page":"136","article-title":"From ICI to ICU: a systematic review of patients with solid tumors who are treated with immune checkpoint inhibitors (ICI) and admitted to the intensive care unit (ICU)","author":"van Dijk","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.opresp.2026.100578_bib0285","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s11864-024-01257-6","article-title":"Management of pulmonary toxicities associated with systemic therapy in non small cell lung cancer","volume":"25","author":"Velimirovic","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0290","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.opresp.2026.100578_bib0295","first-page":"13","article-title":"Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database","author":"Frey","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.opresp.2026.100578_bib0300","first-page":"15","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","author":"Keam","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.opresp.2026.100578_bib0305","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0310","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0315","first-page":"7","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.opresp.2026.100578_bib0320","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100578_bib0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100578_bib0330","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100578_bib0335","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.opresp.2026.100578_bib0340","first-page":"10","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.opresp.2026.100578_bib0345","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.opresp.2026.100578_bib0350","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.opresp.2026.100578_bib0355","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0360","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.opresp.2026.100578_bib0365","first-page":"37","article-title":"Thoracic complications of precision cancer therapies: a practical guide for radiologists in the new era of cancer care1","author":"Nishino","year":"2017","journal-title":"Radiographics"},{"key":"10.1016\/j.opresp.2026.100578_bib0370","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s10147-025-02732-2","article-title":"High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study","volume":"30","author":"Ishida","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0375","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/intimm\/dxaa022","article-title":"Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease","volume":"32","author":"Suzuki","year":"2020","journal-title":"Int Immunol"},{"key":"10.1016\/j.opresp.2026.100578_bib0380","first-page":"21","article-title":"Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","author":"Nishiyama","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.opresp.2026.100578_bib0385","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0390","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/his.14704","article-title":"Immune check-point inhibitor-related pneumonitis: acute lung injury with rapid progression and organising pneumonia with less severe clinical disease","volume":"81","author":"Imran","year":"2022","journal-title":"Histopathology"},{"key":"10.1016\/j.opresp.2026.100578_bib0395","first-page":"9","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.opresp.2026.100578_bib0400","first-page":"9","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.opresp.2026.100578_bib0405","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/curroncol28030201","article-title":"Real world outcomes and hepatotoxicity of infliximab in the treatment of steroid-refractory immune-related adverse events","volume":"28","author":"Araujo","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0410","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00432-021-03750-z","article-title":"Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study","volume":"148","author":"Kowalski","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0415","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.opresp.2026.100578_bib0420","first-page":"6","article-title":"Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab","author":"Ortega Sanchez","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.opresp.2026.100578_bib0425","first-page":"14","article-title":"Case report: nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.opresp.2026.100578_bib0430","first-page":"11","article-title":"Case report: nintedanib for pembrolizumab-related pneumonitis in a patient with non-small cell lung cancer","author":"Xie","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0435","doi-asserted-by":"crossref","first-page":"E37808","DOI":"10.1097\/MD.0000000000037808","article-title":"A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis","volume":"103","author":"Li","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.opresp.2026.100578_bib0440","first-page":"14","article-title":"Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis","author":"Shen","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.opresp.2026.100578_bib0445","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.opresp.2026.100578_bib0450","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.opresp.2026.100578_bib0455","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1159\/000543556","article-title":"Characteristics and risk factors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: a retrospective study","volume":"103","author":"Cui","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.opresp.2026.100578_bib0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304941","article-title":"Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: a systematic review and single-arm meta-analysis","volume":"19","author":"Cui","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.opresp.2026.100578_bib0465","first-page":"28","article-title":"Management of pulmonary toxicity associated with immune checkpoint inhibitors","author":"Delaunay","year":"2019","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.opresp.2026.100578_bib0470","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.21037\/jtd-22-93","article-title":"Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management","volume":"14","author":"Kim","year":"2022","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.opresp.2026.100578_bib0475","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12931-024-02683-8","article-title":"Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy","author":"Kitahara","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.opresp.2026.100578_bib0480","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MCP.0000000000000895","article-title":"Pulmonary adverse events following immune checkpoint inhibitors","volume":"28","author":"Spagnolo","year":"2022","journal-title":"Curr Opin Pulm Med"}],"container-title":["Open Respiratory Archives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663626000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663626000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:40:26Z","timestamp":1781077226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2659663626000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2659663626000421"],"URL":"https:\/\/doi.org\/10.1016\/j.opresp.2026.100578","relation":{},"ISSN":["2659-6636"],"issn-type":[{"value":"2659-6636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitors and Interstitial Lung Disease: A Comprehensive Review of Pathogenesis, Diagnosis, and Management","name":"articletitle","label":"Article Title"},{"value":"Open Respiratory Archives","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.opresp.2026.100578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100578"}}